


STEREOCHEMISTRY ABSTRACTS

P. Allevi, M. Anastasia, P. Ciuffreda and A.M. Sanvito

Tetrahedron: Asymmetry 1993, 4, 1397




ee 84%; $[\alpha]_D^{23} = + 22.8$ (CHCl_3 , c 1)

(4*S*, 2*E*)-4-Hydroxyhept-2-enoic acid

P. Allevi, M. Anastasia, P. Ciuffreda and A.M. Sanvito

Tetrahedron: Asymmetry 1993, 4, 1397




ee 82%; $[\alpha]_D^{23} = + 22.5$ (CHCl_3 , c 1)

(4*S*, 2*E*)-4-Hydroxyoct-2-enoic acid

P. Allevi, M. Anastasia, P. Ciuffreda and A.M. Sanvito

Tetrahedron: Asymmetry 1993, 4, 1397




ee 74%; $[\alpha]_D^{23} = + 22.0$ (CHCl_3 , c 1)

(4*S*, 2*E*)-4-Hydroxynon-2-enoic acid


P. Allevi, M. Anastasia, P. Ciuffreda and A.M. Sanvito

Tetrahedron: Asymmetry 1993, 4, 1397




ee 82%; $[\alpha]_D^{23} = + 19.6$ (CHCl_3 , c 1)

(4*S*, 2*E*)-4-Hydroxydec-2-enoic acid




ee 85%; $[\alpha]_D^{23} = + 18.2$ (CHCl_3 , c 1)

(4*S*, 2*E*)-4-Hydroxyundec-2-enoic acid




ee 83%; $[\alpha]_D^{23} = + 19.2$ (CHCl_3 , c 1)

(4*S*, 2*E*)-4-Hydroxydodec-2-enoic acid







ee 75%; $[\alpha]_D^{23} = -16.5$ (CHCl_3 , c 1)


Methyl (4*R*, 2*E*)-4-hydroxyhept-2-enoate



ee 77%; $[\alpha]_D^{23} = -18.3$ (CHCl_3 , c 1)

Methyl (4*R*, 2*E*)-4-hydroxyoct-2-enoate


ee 95%; $[\alpha]_D^{23} = -22.8$ (CHCl₃, c 1)Methyl (4*R*, 2*E*)-4-hydroxynon-2-enoateee 93%; $[\alpha]_D^{23} = -20.2$ (CHCl₃, c 1)Methyl (4*R*, 2*E*)-4-hydroxydec-2-enoateee 85%; $[\alpha]_D^{23} = -20.3$ (CHCl₃, c 1)Methyl (4*R*, 2*E*)-4-hydroxyundec-2-enoateee 88%; $[\alpha]_D^{23} = -18.0$ (CHCl₃, c 1)Methyl (4*R*, 2*E*)-4-hydroxydodec-2-enoate



E.e.= >98%[by ^1H -NMR as (+)- and (-) Mosher esters]
 $[\alpha]_D^{19} +28.6$ (c 1.0, CHCl_3)
mp 127-129 °C (Hexane and EtOAc)
Source of chirality: Asymm. synth. from L-Phenylalanine
Absolute configuration: 2*R*, 3*S*

$\text{C}_{27}\text{H}_{34}\text{O}_4\text{NP}$


Diethyl (2*R*, 3*S*)-3-Dibenzylamino-2-hydroxy-4-phenylpropylphosphonate



E.e.= >98%[by ^1H -NMR as (+)- and (-) Mosher esters]
 $[\alpha]_D^{19} +39.0$ (c 1.1, CHCl_3)
mp 87-88 °C (Hexane and EtOAc)
Source of chirality: Asymm. synth. from L-Phenylalanine
Absolute configuration: 2*S*, 3*S*

$\text{C}_{27}\text{H}_{34}\text{O}_4\text{NP}$


Diethyl (2*S*, 3*S*)-3-Dibenzylamino-2-hydroxy-4-phenylpropylphosphonate



$[\alpha]_D^{20} -47.5$ (c 1.0, CHCl_3)
an oil
Source of chirality: Asymm. synth. from L-Phenylalanine
Absolute configuration: 4*S*, 5*R*

$\text{C}_{14}\text{H}_{20}\text{O}_5\text{NP}$


(4*S*, 5*R*)-4-Benzyl-5-diethylphosphonooxazolidin-2-one




$[\alpha]_D^{20} -61.5$ (c 1.3, CHCl_3)
an oil
Source of chirality: Asymm. synth. from L-Phenylalanine
Absolute configuration: 4*S*, 5*S*

$\text{C}_{14}\text{H}_{20}\text{O}_5\text{NP}$

(4*S*, 5*S*)-4-Benzyl-5-diethylphosphonooxazolidin-2-one

 $C_{18}H_{26}O_4$ Ethyl (*E*)-(4*R*, 5*R*)-8-benzyloxy-5-hydroxy-4-methyl-2-octenoateE. e = >98 % by 1H NMR in the presence of Eu(TFC)₃ $[\alpha]_D^{24} +29.0$ (c 4.4, CHCl₃)

Source of chirality: Sharpless asymmetric epoxidation

Absolute configuration 4*R*, 5*R* $C_9H_{15}ON$ (8*R*,8a*S*)-hexahydro-8-methyl-5(1*H*)-indolizinoneD. e = >99 % by 1H NMR $[\alpha]_D^{24} -21.5$ (c 0.65, CHCl₃)


Source of chirality: Sharpless asymmetric epoxidation

Absolute configuration 8*R*, 8a*S*(S)-6-(*p*-toluenesulfinyl)hex-5-yn-2-one ethylene acetal

E.e.=100%

 $[\alpha]_D^{23} = +65.8$ (c 0.152, CHCl₃)

Source of chirality: (-)-menthol and well-established Andersen method


Absolute configuration: *S* (based on the mechanism of the Andersen method)Z-(*R*)-5-methyl-6-(*p*-toluenesulfinyl)hex-5-en-2-one ethylene acetal

E.e.=100%

 $[\alpha]_D^{23} = -227.2$ (c 0.340, CHCl₃)


Source of chirality: (-)-menthol

Absolute configuration: *R*




E.e.=100%
 $[\alpha]_D^{23}=-46.6$ (*c* 0.152, CHCl₃)
 Source of chirality: (-)-menthol
 Absolute configuration: *R*

E-(*R*)-5-(3,4-dimethoxyphenyl)-6-(*p*-toluenesulfinyl)-hex-5-en-2-one ethylene acetal




E.e.>98% (by ¹H NMR of MTPA ester after transformation to a cyclohexenol)
 $[\alpha]_D^{23}=+4.31$ (*c* 1.72, CHCl₃)
 Source of chirality: enantiomerically pure sulfoxide derived from (-)-menthol and asymmetric cycloaddition
 Absolute configuration: *R* (assigned by CD exciton method applied to the allylic benzoate of a later product)

methyl (1-methyl-4-oxo-cyclohex-2-enyl)acetate



3a,4,5,7a-tetrahydro-3a,6-dimethyl-2(3*H*)-benzofuranone

E.e.>98% (by ¹H NMR of MTPA ester after transformation to a cyclohexenol)
 $[\alpha]_D^{23}=-15.0$ (*c* 0.181, CHCl₃)
 m.p. 76-77 °C
 Source of chirality: enantiomerically pure sulfoxide derived from (-)-menthol and asymmetric cycloaddition
 Absolute configuration: 3a*R*,7a*R* (assigned by CD exciton chirality method applied to the allylic benzoate derived from a later product)




methyl (1-(3,4-dimethoxyphenyl)-4-oxo-cyclohex-2-enyl)acetate

E.e.=100% (determined by comparison of optical rotation after transformation to (+)-mesembrine)
 $[\alpha]_D^{23}=+47.3$ (*c* 0.237, CHCl₃)
 m.p. 82-83 °C
 Source of chirality: enantiomerically pure sulfoxide derived from (-)-menthol and asymmetric cycloaddition
 Absolute configuration: *S* (assigned by comparison of optical rotation after transformation to (+)-mesembrine)

H. Kosugi, Y. Miura, H. Kanna, and H. Uda

Tetrahedron: Asymmetry 1993, 4, 1409



3a-(3,4-dimethoxyphenyl)octahydro-1-methyl-(3a,cis)-6H-indole-2,6-dione

E.e.=100% (determined by comparison of the optical rotation after conversion to (+)-mesembrine)


$[\alpha]_D^{23} +55.6$ (*c* 0.345, CHCl₃)

Source of chirality: enantiomerically pure sulfoxide derived from (-)-menthol and asymmetric cycloaddition

Absolute configuration: 3a*R*,7a*R* (assigned by comparison of optical rotation after transformation to (+)-mesembrine)

H. Kosugi, Y. Miura, H. Kanna, and H. Uda

Tetrahedron: Asymmetry 1993, 4, 1409



(+)-mesembrine

E.e.=100% (determined by comparison of the reported optical rotation value)


$[\alpha]_D^{23} +60.0$ (*c* 0.164, MeOH)

Source of chirality: enantiomerically pure sulfoxide derived from (-)-menthol and asymmetric cycloaddition

Absolute configuration: 3a*R*,7a*R* (assigned by comparison of optical rotations)

W. Behnen, Th. Mehler, J. Martens*

Tetrahedron: Asymmetry 1993, 4, 1413



(*S*)-1-methyl-2-(diphenylhydroxymethyl)azetidine

E.e. under investigation


$[\alpha]_D^{20} = +39.3$ (*c* = 5.0, CHCl₃)

Source of chirality: (*S*)-azetidinecarboxylic acid

Absolute configuration S

Marek M. Kabat

Tetrahedron: Asymmetry 1993, 4, 1417



C₁₃H₂₅FO
3-fluoro-tridecan-2-one

E.e.=97% (by ¹H nmr with tris[3-(heptafluoropropylhydroxy-


methylene)-(+)-camphorato]-europium (III)).

$[\alpha]_D^{25} = +50.7$ (*c* 1.08, CH₂Cl₂)

Source of chirality: Sharpless asymmetric method of olefin epoxidation using the L(+)-diethyl tartrate/^tBuOOH/Ti(O*i*Pr)₄ system.

Absolute configuration: 3*R*

(assigned by a general rule of Sharpless asymmetric epoxidation of olefins and S_N2 opening of the chiral allene oxide ring by fluoride)



$C_{14}H_{27}FO$
4-fluoro-tridecan-3-one


E.e.=97% (by 1H nmr with tris[3-(heptafluoropropylhydroxy-methylene)-(+)-camphorato]-europium (III)).

$[\alpha]_D^{25}=+50.8$ (c 1.14, CH_2Cl_2)

Source of chirality: Sharpless asymmetric method of olefin epoxidation using the L(+)-diethyl tartrate/ t BuOOH/Ti(O*i*Pr)₄ system.

Absolute configuration: 4R

(assigned by a general rule of Sharpless asymmetric epoxidation of olefins and S_N2 opening of the chiral allene oxide ring by fluoride)




$C_{25}H_{21}NO_4$
(*S*,*S*,*S*,*S*)-2-(*N*-benzylcarbamoyl)-1-(2-hydroxyphenyl)-2a,8b-dihydro-3*H*-cyclobuta[*c*]chromen-3-one

$[\alpha]_D -155$ (c 0.5, acetone); mp 209.0-210.5 °C

Absolute configuration: (*S*,*S*,*S*,*S*)-

Source of chirality: (*S*,*S*,*S*,*S*)-*anti* head-to-head coumarin dimer



$C_{21}H_{32}NO_2Ir$
(S_Ir,S_N,S_C)-(η^5 -pentamethylcyclopentadienyl)proline (*tert*-butylacetylidyne)iridium(III)


E.e. = 100 %

$[\alpha]_D^{20} = -4$ (c 0.4, $CHCl_3$)

Absolute configuration S_Ir,S_N,S_C

Source of chirality: [$(\eta^5-C_5Me_5)Ir(L\text{-proline})Cl$]

(D. Carmona, A. Mendoza, F.J. Lahoz, L.A. Oro, M.P. Lamata and E. San José, *J. Organomet. Chem.* 1990, 396, C17.)



$C_{21}H_{32}NO_2Ir$
(R_Ir,S_N,S_C)-(η^5 -pentamethylcyclopentadienyl)proline (*tert*-butylacetylidyne)iridium(III)


E.e. = 100 %

$[\alpha]_D^{20} = +31$ (c 0.4, $CHCl_3$)

Absolute configuration R_Ir,S_N,S_C (X-ray crystal structure)

Source of chirality: [$(\eta^5-C_5Me_5)Ir(L\text{-proline})Cl$]


(D. Carmona, A. Mendoza, F.J. Lahoz, L.A. Oro, M.P. Lamata and E. San José, *J. Organomet. Chem.* 1990, 396, C17.)




(2S,5R)-2-Hydroxyethyl-5-butylpyrrolidine

E.e.>98%, $[\alpha]^{22}_D=-20.2$ ($c=0.56$, CHCl_3)Source of chirality: (S)-pyroglutamic acid
(U.C.I.B. France)


Absolute configuration : 2(S), 5(R)


(2S,5R)-1-carbobenzyloxy-2-hydroxyethyl-
5-butylpyrrolidineE.e.>98%, $[\alpha]^{20}_D=-31.7$ ($c=1.25$, CHCl_3)Source of chirality: (S)-pyroglutamic acid
(U.C.I.B. France)

Absolute configuration : 2(S), 5(R)

(2S,5R)-1-carbobenzyloxy-2-(1-oxoethyl)-
5-butylpyrrolidineE.e.>98%, $[\alpha]^{20}_D=-44.7$ ($c=1.05$, CHCl_3)Source of chirality: (S)-pyroglutamic acid
(U.C.I.B. France)

Absolute configuration : 2(S), 5(R)

(2R,5R)-1-carbobenzyloxy-2-(4-oxoheptyl)-
5-butylpyrrolidineE.e.>98%, $[\alpha]^{20}_D=-52.5$ ($c=0.63$, CH_2Cl_2)Source of chirality: (S)-pyroglutamic acid
(U.C.I.B. France)Absolute configuration : 2(R), 5(R)
(Assigned by correlation of specific rotation
with literature)




(3R,5R,9R)-3-Butyl-5-propyloctahydroindolizine
(-) - Gephyrotoxine 223AB

E.e.>98%, $[\alpha]_D^{20} = -103$ ($c=1.12$, Hexane)

Source of chirality: (S)-pyroglutamic acid
(U.C.I.B. France)

Absolute configuration : 3(R), 5(R), 9 (R)
(Assigned by correlation of specific rotation
with literature)




2-Tert-butyl-1,3-benzodioxole-
4-carboxylic acid

$[\alpha]_D^{20} + 52.6$ ($c\ 0.5$, MeOH)

E.e. = >95 % [1H -NMR as (-)-cinchonidine salt]

Source of chirality : (-)-cinchonidine

Absolute configuration : 2S (assigned by CD)




$[\alpha]_D^{20} -32.0$ ($c = 1.11$, CCl_4)

Source of chirality: Sharpless epoxidation


Absolute configuration: 2S,3S
(assigned by conversion to (S)-ketoprofen)

3-Methyl-3-(4'-trimethylsilylphenyl)
oxiranemethanol 3,5-dinitrobenzoate




$[\alpha]_D^{20} -20.0$ ($c = 2.86$, CCl_4)

Source of chirality: Sharpless epoxidation



Absolute configuration: 2S,3S
(assigned by conversion to (S)-ibuprofen)

3-Methyl-3-(4'-trimethylsilylphenyl)
oxiranemethanol

C8H17NO3

E.e. >99 % [by chiral phase HPLC on the dibenzoate derivative
(Nucleosil Chiral 2®, Macherey-Nagel), n-heptane/1,4-dioxane: 70/30]


$[\alpha]^{20}_D = -88 \pm 2$ (c = 1 in CH_2Cl_2)

Source of chirality: natural D(-)pantolactone

Absolute configuration: 2R

(assigned by comparision with D(-)pantolactone)

D(-)2R,4-Dihydroxy-3,3-dimethyl-N,N-dimethyl-butylamide

C11H20BNO3


$[\alpha]^{20}_D = -140 \pm 2$ (c = 1 in CH_2Cl_2)

Source of chirality: natural D(-)pantolactone

Absolute configuration: 4R

(assigned by comparision with D(-)pantolactone)

2-Allyl-5,5-dimethyl-1,3,2-dioxaborinane-4R-N,N-dimethyl carboxamide


C16H15NO2

E.e. ≥ 97% (determined for product of reaction with an ester enolate)

$[\alpha]_D^{20} = +89.7$ (c = 2.5, benzene)

source of chirality : (R)-2-phenylglycine

absolute configuration : R


C18H18N2O3

E.e. = 97% (by HPLC on Daicel Chiralcel OD)

$[\alpha]_D^{20} = +132.1$ (c = 2, benzene)

source of chirality : (R)-2-phenylglycine

absolute configuration : 3S, 4S, αS (from X-Ray structure)




d.e.>95% by NMR

 $[\alpha]_D^{20} - 55.68$ ($c = 1, \text{CHCl}_3$)Source of chirality : natural and diastereoselective
methylation


Absolute configuration : 2R

$C_{28}H_{46}N_2O_4S$
 $(2R)-(1S,2R,4R)$ -10-dicyclohexylsulfamoylisobornyl 2-cyano-2-methylbutanoate

 $[\alpha]_D^{20} + 3.1$ ($c = 1, \text{CHCl}_3$)Source of chirality : natural and diastereoselective
methylation


Absolute configuration : 2R

$C_6H_9NO_2$
 $(2R)$ -2-cyano-2-methylbutanoic acid

 $[\alpha]_D^{20} - 1.7$ ($c = 0.8, \text{CHCl}_3$)Source of chirality : natural and diastereoselective
methylation

Absolute configuration : 2R

$C_8H_{14}N_2O_2$
 $(2R)$ -2-ethoxycarbonylamino-2-methylbutyronitrile



e.e.>99%

 $[\alpha]_D^{20} - 11.28$ ($c = 5\%, \text{H}_2\text{O}$)Source of chirality : natural and diastereoselective
methylation

Absolute configuration : 2R

$C_5H_{11}NO_2$
 $(2R)$ -amino-2-methylbutanoic acid



(R)

 $C_6H_{12}O$


3,3-Dimethyl-1,2-epoxybutane

E.e.= 92% [by HPLC as BGIT derivative]

 $[\alpha]_D^{25} = -18.4$ ($c = 1.7$, $CHCl_3$)

Source of chirality: enzymatic hydrolysis

Absolute configuration: R


 $C_6H_{13}ClO$

3,3-Dimethyl-1-chloro-2-butanol

E.e.> 98% [by GC using Cyclodex β -I/P] $[\alpha]_D^{25} = -41.0$ ($c = 1.3$, $CHCl_3$)

Source of chirality: enzymatic hydrolysis

Absolute configuration: R


 $C_8H_{14}Cl_2O_2$

3,3-Dimethyl-1-chloro-2-[chloracetoxy]-butane

E.e > 98% [by GC using Cyclodex β I/P] $[\alpha]_D^{25} = -15.5$ ($c = 2.2$, $CHCl_3$)

Source of chirality: enzymatic hydrolysis

Absolute configuration: R

 $C_{12}H_{27}NO$


1-(Diisopropylamino)-3,3-dimethylbutan-2-ol

E.e.= 97% [by precursor]

 $[(\alpha)]_D^{25} = +76.7$ ($c = 1.0$, $CHCl_3$)

Source of chirality: enzymatic hydrolysis

Absolute configuration: S


 $C_{10}H_{21}NO_2$

3,3-Dimethyl-1-morpholinobutan-2-ol

E.e.= 97% [by precursor]
 $[\alpha]_D^{25} = +68.1$ ($c = 1.0$, $CHCl_3$)


Source of chirality: enzymatic hydrolysis

Absolute configuration: S




1-Methyl-3,4-bis[(tert-butyldimethylsilyl)oxy]-5-benzyl-2-pyrrolidinone

D.e.=100% [by HPLC using Chiralpak AS (Daicel)]
 $[\alpha]_D^{24}+74.8$ (c 3.57, $CHCl_3$)

Source of chirality: natural and synthetic by deoxygenation of α -hydroxylactamAbsolute configuration 3R,4S,5S
 (assigned by observed chemical shift and vicinal coupling constants) $C_8H_{15}NO_2$ 1,2-Dihydroxyindolizidine
 (Lentiginosine)

E.e.=100%
 D.e.=92% [by HPLC using Chiralpak AS (Daicel)]
 $[\alpha]_D^{23}+0.19$ (c 6.10, $MeOH$)

Source of chirality: L-tartaric acid


Absolute configuration 1S,2S,8aS
 (assigned by observed chemical shift and vicinal coupling constants of synth. intermed.) $C_{22}H_{30}N_2O_2 \cdot 2HCl$

D.e.= 100% [by HPLC analysis of free amine]
 $[\alpha]_D^{22}+58.6$ (c 0.6, $MeOH$)

Source of chirality: catalytic asymmetric hydrogenation of amino ketone derivatives

Absolute configuration: S, R

1-(2-methoxy-2-phenylethyl)-4-(3-hydroxy-3-phenylpropyl)piperazine hydrochloride




D.e.= 98% [by HPLC analysis of free amine]

$[\alpha]_D^{22} +19.2$ (*c* 0.7, MeOH)

Source of chirality: catalytic asymmetric hydrogenation of amino ketone derivatives

Absolute configuration: S, S

1-(2-methoxy-2-phenylethyl)-4-(3-hydroxy-3-phenylpropyl)piperazine hydrochloride



$C_{25}H_{23}N_3O_2$

2,6-Bis[(*S*)-4'-benzyloxazolin-2'-yl]pyridine

E.e. = 100 %

$[\alpha]_D^{22} = -71.7$ (*c* 1.02, CH_2Cl_2)


Source of chirality : natural

Absolute configuration: 4'S,4"S

(derived from L-phenylalanine)

Source of chirality: enantioselective hydrolysis with the cultured cells of *M. polymorpha*

Absolute configuration: assigned by 1H NMR of corresponding MTPA ester




1*R*,2*R*

E.e.=80.0%

$[\alpha]_D^{25} = -38.2$ (*c* 9.6, EtOH)

Source of chirality: enantioselective hydrolysis with the cultured cells of *M. polymorpha*


Absolute configuration: assigned by 1H NMR of corresponding MTPA ester



1*S*,2*S*


E.e.=99.5%

$[\alpha]_D^{25} = +69.9$ (*c* 0.64, EtOH)

 $C_{21}H_{31}NO_4$ 4-Androsten-17- β -ol-3-one 3-(O-carboxymethyl) oxime

Diastereomeric purity is 80 % determined by HPLC
Absolute configuration *anti:syn* assigned by 1H NMR


Source of chirality: enzymatic hydrolysis

 $C_{23}H_{33}NO_4$

4-Pregnen-3,20-dione 3-(O-carboxymethyl) oxime


Diastereomeric purity is 80 % determined by HPLC
Absolute configuration *anti:syn* assigned by 1H NMR

Source of chirality: enzymatic hydrolysis

 $C_{23}H_{33}NO_7$ 4-Pregnen-11- β , 17, 21-triol-3, 20-dione 3-(O-carboxymethyl) oxime

Diastereomeric purity is 94 % determined by HPLC
Absolute configuration *anti:syn* assigned by 1H NMR


Source of chirality: enzymatic hydrolysis

 $C_{23}H_{33}NO_5$

4-Pregnen-17-ol-3,20-dione 3-(O-carboxymethyl) oxime

Diastereomeric purity is 86 % determined by HPLC
Absolute configuration *anti:syn* assigned by 1H NMR

Source of chirality: enzymatic hydrolysis

 $C_6H_{10}F_3NO_2$

(R)-(+)-[1-(hydroxymethyl)propyl]tri-fluoroacetamide

m.p. 90°C


 $[\alpha]_D^{22} +22$ (*c*=1, MeOH)

ee : 100%

Chiral source :

(R)-(-)-2-aminobutan-1-ol

Absolute configuration : R

 $C_6H_{12}F_3NO$

(R)-(-)-2-(2,2,2-trifluoroethylamino)butan-1-ol


 $[\alpha]_D^{22} -9.7$ (*c*=6, MeOH)

ee : 100%

Chiral source :

(R)-(-)-2-aminobutan-1-ol

Absolute configuration : R

 $C_{11}H_{16}FNO$ (R)-(-)-2-(2-fluorobenzylamino)butan-1-ol

m.p. 65°C


 $[\alpha]_D^{22} -23.7$ (*c*=3.25, MeOH)

ee : 100%

Chiral source :

(R)-(-)-2-aminobutan-1-ol

Absolute configuration : R

 $C_{15}H_{18}F_3NO_2$

(R)-(+)-N-(2,2,2-trifluoroethyl)-N-[1-(hydroxymethyl)propyl]cinnamamide





 $[\alpha]_D^{22} +3$ (*c*=2, MeOH)





ee : 100%


Chiral source :

(R)-(-)-2-aminobutan-1-ol

Absolute configuration : R








$[\alpha]_D$ -23.7 (PhH)
de : 88% (^{19}F NMR)
Chiral source :
(R)-(-)-2-aminobutan-1-ol
Absolute configuration : (R,R)

 $\text{C}_{20}\text{H}_{30}\text{F}_3\text{NO}_2$


(R,R)-(-)-N-(2,2,2-trifluoroethyl)-N-[1-(hydroxymethyl)propyl]-3-phenyloctanamide



$[\alpha]_D$ -20.1 (PhH)
de : 87% (^{19}F NMR)
Chiral source :
(R)-(-)-2-aminobutan-1-ol
Absolute configuration : (R,R)

 $\text{C}_{21}\text{H}_{32}\text{F}_3\text{NO}_2$


(R,R)-(-)-N-(2,2,2-trifluoroethyl)-N-[1-(hydroxymethyl)propyl]-3-phenylnonanamide



$[\alpha]_D$ -19 (PhH)
de : 88% (^{19}F NMR)
Chiral source :
(R)-(-)-2-aminobutan-1-ol
Absolute configuration : (R,R)

 $\text{C}_{22}\text{H}_{36}\text{F}_3\text{NO}_2$


(R,R)-(-)-N-(2,2,2-trifluoroethyl)-N-[1-(hydroxymethyl)propyl]-3-phenylundecanamide



E.e.=100% [derived from optically pure norephedrine]
 $[\alpha]_D^{22} = +12.8$ (c 1.0, MeOH)
Source of chirality: norephedrine
Absolute configuration 1S,2R

 $\text{C}_{11}\text{H}_{18}\text{NO}_3\text{PS}$

N-dimethoxyphosphorylothioly norephedrine




E.e.=100% [derived from optically pure norephedrine]

 $[\alpha]_D^{22} = -16.7$ (c 1.3, MeOH)

Source of chirality: norephedrine

Absolute configuration 1S,2R

C13H22NO3PS*N*-diethoxyphosphinothioyl norephedrine

E.e.=100% [derived from optically pure norephedrine]

 $[\alpha]_D^{22} = -16.1$ (c 0.9, MeOH)

Source of chirality: norephedrine

Absolute configuration 1S,2R


C11H18NOPS*N*-dimethylphosphinothioyl norephedrineE.e. = 92% (based on the e.e. of the corresponding γ -lactone) $[\alpha]_D = -3.7$ (c = 1.0, CHCl_3)

Source of chirality: asymmetric deprotonation

Absolute configuration R

C16H24OSi

(R)-(-)-1-Triethylsiloxy-3-phenylcyclobut-1-ene


E.e. = 78% (based on the e.e. of the corresponding γ -lactone) $[\alpha]_D = +46.3$ (c = 1.0, CHCl_3)

Source of chirality: asymmetric deprotonation

Absolute configuration R

C17H26OSi

(R)-(+)-1-Triethylsiloxy-3-methyl-3-phenylcyclobut-1-ene


E.e. = 92% (by comparison of $[\alpha]_D$ with that reported) $[\alpha]_D = +47.6$ ($c = 0.7$, CHCl_3)

Source of chirality: asymmetric deprotonation

Absolute configuration S



(S)-(+)-3-Phenylbutyro-1,4-lactone


E.e. = 78% (determined by HPLC analysis using the chiral column
CHIRALCEL OJ) $[\alpha]_D = +13.6$ ($c = 0.7$, CHCl_3)

Source of chirality: asymmetric deprotonation

Absolute configuration S




(S)-(+)-3-Methyl-3-phenylbutyro-1,4-lactone

E.e. = 72% (by comparison of $[\alpha]_D$ with that reported) $[\alpha]_D = -14.4$ ($c = 0.5$, EtOH)

Source of chirality: asymmetric deprotonation

Absolute configuration S

(S)-(-)-2-Methyl-2-phenylsuccinic acid


E.e. = >98% [by ^1H NMR with $\text{Eu}(\text{ffc})_3$] $[\alpha]_{546}^{22} -284$ ($c 0.21$, C_6H_6)

Source of chirality: Resolution

Absolute configuration: R

(assigned by comparison with Chem. Comm., 1986, 607)


Iron(cyclopentadienyl)(carbon)(triphenylphosphine)acetyl



$C_{27}H_{18}S_2$
2-Methyl-9-(9'H-thioxanthene-9'-ylidene)-9H-thioxanthene

CD [$\lambda_{\text{max}}/\text{nm } (\Delta \epsilon)$]: 225 (-14.3) 244 (-14.6) 266 (3.8)
 282 (-11.2) 303 (8.5) 330 (3.6)


Source of chirality: separation on
(+)-poly(triphenylmethyl)methacrylate
Absolute configuration is unknown



$C_{28}H_{20}S_2$
Cis-2-methyl-9-(2'-methyl-9'H-thioxanthene-9'-ylidene)-9H-thioxanthene

CD [$\lambda_{\text{max}}/\text{nm } (\Delta \epsilon)$]: 227 (-29.6) 246 (-25.6) 267 (6.6)
 284 (-18.0) 304 (16.0) 330 s (9.3)


Source of chirality: separation on
(+)-poly(triphenylmethyl)methacrylate
Absolute configuration is unknown



$C_{28}H_{20}S_2O$
Cis-2-methoxy-9-(2'-methyl-9'H-thioxanthene-9'-ylidene)-9H-thioxanthene

CD [$\lambda_{\text{max}}/\text{nm } (\Delta \epsilon)$]: 226 (-18.4) 247 (-27.4) 267 (12.9)
 285 (-32.8) 306 (24.8) 335 s (9.9)


Source of chirality: separation on
(+)-poly(triphenylmethyl)methacrylate
Absolute configuration is unknown



$C_{28}H_{20}S_2O$
Trans-2-methoxy-9-(2'-methyl-9'H-thioxanthene-9'-ylidene)-9H-thioxanthene

CD [$\lambda_{\text{max}}/\text{nm } (\Delta \epsilon)$]: 230 (-6.5) 248 (5.9) 267 (-4.7)
 288 (16.7) 306 (-8.2) 330 s (-2.1)

Source of chirality: separation on
(+)-poly(triphenylmethyl)methacrylate
Absolute configuration is unknown




CD [λ_{max} /nm ($\Delta \epsilon$)]: 227 (-21.1) 247 (-21.3) 267 (14.4)
 286 (-33.5) 306 (22.8) 335 s (8.1)

Source of chirality: separation on
(+)-poly(triphenylmethyl)methacrylate
Absolute configuration is unknown

$C_{28}H_{20}S_2O_2$

Cis-2-methoxy-9-(2'-methoxy-9'H-thioxanthene-9'-ylidene)-9H-thioxanthene




E.e. =90% (det. by 1H NMR using Eu (tfc)₃)

$[\alpha]_D^{20} = +8.1$ ($c = 5.92$ in CH_2Cl_2)

Source of chirality: (R)-(+)-1-phenylethylamine

Absolute configuration: S

(S)-(+)-2-Ethyl-2-[2'carboxymethyl ethyl]cyclopentanone




$[\alpha]_D^{20} = -6.2$ ($c = 6.09$ in CH_2Cl_2)

Source of chirality: (R)-(+)-1-phenylethylamine

Absolute configuration: S

(S)-(-)-2-Ethyl-2-[2'carboxymethyl ethyl]cyclopentanone ethylene glycol ketal




$[\alpha]_D^{20} = -10.16$ ($c = 1.87$ in CH_2Cl_2)

Source of chirality: (R)-(+)-1-phenylethylamine

Absolute configuration: S

(S)-(-)-2-Ethyl-2-[2'amide ethyl]-cyclopentanone ethylene glycol ketal




$[\alpha]_D^{20} = -7.2$ ($c = 2.08$ in CH_2Cl_2)

Source of chirality: (R)-(+)-1-phenylethylamine

Absolute configuration: S

(S)-(-)-2-Ethyl-2-[3'amine propyl]-cyclopentanone ethylene glycol ketal




$[\alpha]_D^{20} = +5.1$ ($c = 1.03$ in CH_2Cl_2)

Source of chirality: (R)-(+)-1-phenylethylamine

Absolute configuration: S

(S)-(+)-4a-Ethyl-3,4,4a,5,6,7-hexahydro-2H-1-pyridine



E.e.=90% (by ^1H NMR of MTPA amide of the corresponding α -furfuryl amine)


$[\alpha]_D = -85.2$ ($c 0.4$, EtOH)

Source of Chirality: Sharpless kinetic resolution

Absolute Configuration: S

$\text{C}_{13}\text{H}_{13}\text{NO}_2$

(S)-N-Benzoyl-1-(α -furyl)-ethylamine



E.e.=90% (by ^1H NMR of MTPA amide of the corresponding α -furfuryl amine)

$[\alpha]_D = -82.2$ ($c 0.4$, EtOH)


Source of Chirality: Sharpless kinetic resolution

Absolute Configuration: S

$\text{C}_{15}\text{H}_{17}\text{NO}_2$

(S)-N-Benzoyl-1-(α -furyl)-n-butylamine

Wei-Shan Zhou,* Xue-You Zhu, and Jie-Fei Cheng


E.e.=91%(by ^1H NMR of MTPA amide of the corresponding α -furyl amine) $[\alpha]_D = -78.2(c\ 0.5, \text{EtOH})$

Source of Chirality: Sharpless kinetic resolution

Absolute Configuration: S

(S)-N-Benzoyl-1-(α -furyl)-3-methylbutylamine

D. M. Rotstein and K. A. M. Walker




(2S)-1-[2-(2,6-Dichlorophenylthio)-4-(4-chlorophenyl)butyl]-1H-imidazole nitrate


E.e. = 99.4% by chiral HPLC

 $[\alpha]_D^{25} = +22.7 (c, 0.4, \text{EtOH})$ Source of chirality: R-(\leftarrow)-glycidyl tosylate

D. M. Rotstein and K. A. M. Walker




E.e. = 100 % by chiral HPLC

 $[\alpha]_D^{25} = +23.6 (c, 0.4, \text{CHCl}_3)$ Source of chirality: R-(\leftarrow)-glycidyl tosylate

R-(+)-1-[2-Hydroxy-4-(4-chlorophenyl)butyl]-1H-imidazole


Guo-qiang Lin*, Zhi-cai Shi, and Chun-ming Zeng

 $[\alpha]_D^{25} = +18.8 (c\ 0.36, \text{CH}_2\text{Cl}_2)$

Source of chirality: (2R,3S)-1,2-epoxy-4-penten-3-ol

Absolute configuration: 3S,4S


5-benzylthio-(3S,4S)-3,4-dihydroxy-1-pentene.

**C₁₁H₁₄O₂S** $[\alpha]_D^{25} = +12.4$ (*c* 1.45, CHCl₃)

Source of chirality: (2R,3S)-1,2-epoxy-4-penten-3-ol

Absolute configuration: 3S, 4S


5-phenylthio-(3S,4S)-3,4-dihydroxy-1-pentene

**C₁₁H₁₅NO₂S** $[\alpha]_D^{25} = +37.5$ (*c* 1.35, CHCl₃)

Source of chirality: (2R,3S)-1,2-epoxy-4-penten-3-ol

Absolute configuration: 3S, 4S


5-(o-aminophenyl)thio-(3S,4S)-3,4-dihydroxy-1-pentene

**C₈H₁₆O₂S₂** $[\alpha]_D^{25} = +1.4$ (*c* 1.08, CHCl₃)

Source of chirality: (2R,3S)-1,2-epoxy-4-penten-3-ol

Absolute configuration: 3S, 4S


5-(3'-mercaptopropropyl)thio-(3S,4S)-3,4-dihydroxy-1-pentene

**C₁₂H₁₄O₃S** $[\alpha]_D^{25} = -3.4$ (*c* 1.94, CHCl₃)

Source of chirality: (2R,3S)-1,2-epoxy-4-penten-3-ol


Absolute configuration: 3S, 4S

5-benzoylthio-(3S,4S)-3,4-dihydroxy-1-pentene

 $C_{12}H_{16}O_3S$ $[\alpha]_D^{25} = +2.1$ (*c* 0.29, CHCl₃)

Source of chirality: (2R,3S)-1,2-epoxy-4-penten-3-ol


Absolute configuration: 3S, 4S

5-(*o*-hydroxymethylphenyl)thio-(3S,4S)-3,4-dihydroxy-1-pentene $C_{11}H_{13}NOS$ $[\alpha]_D^{25} = -37.3$ (*c* 0.69, CH₂Cl₂)

Source of chirality:

Absolute configuration: 3S, 3R


3R-3-(3'S-3'-hydroxy-1'-propenyl)-2,3,4-trihydro-[1,4]-benzothiazine

 $C_{11}H_{13}NOS$ $[\alpha]_D^{25} = -6.2$ (*c* 0.60, CH₂Cl₂)

Source of chirality:


Absolute configuration: 3S, 4R

(3S,4R)-3-hydroxy-4-vinyl-2,3,4,5-tetrahydro-[1,5]-benzothiazepine


 $C_{10}H_{14}O_3$ E.e. = 58% (determined by ¹H NMR analysis of the corresponding MTPA ester) $[\alpha]_D = +6.25$ (*c* = 1.0, CHCl₃)Source of chirality: asymmetric reduction with (*S*)-oxazaborolidine and BH₃

Absolute configuration 7R (estimated based on a mechanism proposed for the asymmetric reduction)


(7R)-3,3-Ethylenedioxybicyclo[4.2.0]oct-1(6)-en-7-ol




E.e. = >99% (determined by ^1H NMR analysis of the corresponding MTPA ester)
 $[\alpha]_D = +30.8$ ($c = 1.0, \text{CHCl}_3$)
 $\text{Mp} = 75\text{--}76^\circ\text{C}$ (from methanol)
Source of chirality: asymmetric reduction with (*S*)-oxazaborolidine and BH_3
Absolute configuration 1*R*, 6*S*, 7*R*
(1*R*,6*S*,7*R*)-7-*endo*-*tert*-Butyldiphenylsiloxybicyclo[4.2.0]octan-3-one
 $\text{C}_{24}\text{H}_{30}\text{O}_2\text{Si}$




E.e. = >99% (determined by ^1H NMR analysis of the corresponding MTPA ester)
 $[\alpha]_D = -39.0$ ($c = 1.0, \text{CHCl}_3$)
 $\text{Mp} = 65\text{--}68^\circ\text{C}$
Source of chirality: asymmetric reduction with (*S*)-oxazaborolidine and BH_3
Absolute configuration 6*S*, 7*R*
(6*S*,7*R*)-7-*endo*-*tert*-Butyldiphenylsiloxybicyclo[4.2.0]oct-1-en-3-one
 $\text{C}_{24}\text{H}_{28}\text{O}_2\text{Si}$



E.e. = >99% (determined by ^1H NMR analysis of the corresponding MTPA ester)
 $[\alpha]_D = -25.2$ ($c = 0.35, \text{CHCl}_3$)
Source of chirality: asymmetric reduction with (*S*)-oxazaborolidine and BH_3
Absolute configuration 1*R*, 6*S*, 7*R*
 $\text{C}_9\text{H}_{14}\text{O}_2$
(1*R*,6*S*,7*R*)-7-*endo*-Hydroxy-1-methylbicyclo[4.2.0]octan-3-one




E.e. = >99% (based on the enantiomeric excess of the starting material)
 $[\alpha]_D = +8.0$ ($c = 0.1, \text{CHCl}_3$)
Source of chirality: asymmetric reduction with (*S*)-oxazaborolidine and BH_3
Absolute configuration 1*R*, 6*S*
 $\text{C}_9\text{H}_{14}\text{O}$
(1*R*,6*S*)-1-Methylbicyclo[4.2.0]octan-3-one




Spiro [(hexahydro-4,4,7-trimethyl-1,3-benzoxathiane)-2,1'-(dimethylcyclopentane-3'-4'-dicarboxylate)]

$[\alpha]_D = -25.5$ ($c=2.46$, CHCl_3)
e.e > 98%, (RMN)
m.p. 107-108.
Absolute configuration: 7R, 9R, 10S, 3'S, 4'S.
Source of chirality: resolution.




5-methyl-2-(1-mercaptopro-1-methylethyl)cyclohexanol

$[\alpha]_D = -6$ ($c=3.95$, CHCl_3)
e.e > 98%
Liquid
Absolute configuration: 1R, 2R, 5R
Source of chirality: (+) pulegone



$\text{C}_9\text{H}_{12}\text{O}_5$
Dimethyl 4-oxocyclobutane dicarboxylate

$[\alpha]_D = +136$ ($c=0.66$, CHCl_3), (lit. +134.4)
e.e > 98%
liquid
Absolute configuration: 1S, 2S.
Source of chirality: resolution.




$\text{C}_{17}\text{H}_{24}\text{OS}$
Hexahydro-4,4,7-trimethyl-1-2-phenyl-1,3-benzoxathiane

$[\alpha]_D = +56.5$ ($c=2.52$, CHCl_3)
e.e > 98%, (RMN)
m.p. 96-7°C
Absolute configuration: 2R, 7R, 9R, 10R.
Source of chirality: (+) pulegone

M. Miyashita, Y. Toshimitsu, T. Shiratani, H. Irie

Tetrahedron: Asymmetry 1993, 4, 1573




Ethyl 6-benzyloxy-4,5-epoxy-2-hexenoate

E.e. > 87% by precursor
 $[\alpha]_D^{20} -6.1 (c \ 1.12, \text{CHCl}_3)$
Source of chirality: D-Tartaric acid and
asymmetric epoxidation
Absolute configuration: 4R, 5S

M. Miyashita, Y. Toshimitsu, T. Shiratani, H. Irie

Tetrahedron: Asymmetry 1993, 4, 1573





Ethyl 6-benzyloxy-5-hydroxy-4-methyl-2-hexenoate

E.e. > 87% by precursor
 $[\alpha]_D^{18} -37.3 (c \ 1.10, \text{CHCl}_3)$
Source of chirality: D-Tartaric acid and
asymmetric epoxidation
Absolute configuration: 4S, 5R

M. Miyashita, Y. Toshimitsu, T. Shiratani, H. Irie

Tetrahedron: Asymmetry 1993, 4, 1573





6-Benzyl-4-methyl-delta-valerolactone

E.e. > 87% by precursor
 $[\alpha]_D^{16} -31.7 (c \ 0.98, \text{CHCl}_3)$
Source of chirality: D-Tartaric acid and
asymmetric epoxidation
Absolute configuration: 4S, 5R


M. Miyashita, Y. Toshimitsu, T. Shiratani, H. Irie

Tetrahedron: Asymmetry 1993, 4, 1573




6-Benzyl-2,4-dimethyl-delta-valerolactone

E.e. > 99% (recrystallization)
 $[\alpha]_D^{24} -21.9 (c \ 0.68, \text{CHCl}_3)$
Source of chirality: D-Tartaric acid and
asymmetric epoxidation
Absolute configuration: 2S, 4S, 5R




E.e. > 99% by precursor
 $[\alpha]_D^{22} -9.02 (c \ 0.37, \text{CHCl}_3)$
 Source of chirality: D-Tartaric acid and asymmetric epoxidation
 Absolute configuration: 2S, 4S, 5R

6-Benzyl-2,4-dimethyl-5-hydroxy-N-methoxy-N-methylhexanamide




E.e. > 99% by precursor
 $[\alpha]_D^{20} -0.39 (c \ 0.86, \text{CHCl}_3)$
 Source of chirality: D-Tartaric acid and asymmetric epoxidation
 Absolute configuration: 2S, 4S, 5R

5-Acetoxy-2,4-dimethyl-6-methanesulfonyloxy-N-methoxy-N-methylhexanamide





E.e. > 99% by precursor
 $[\alpha]_D^{21} +28.7 (c \ 0.12, \text{CHCl}_3)$
 Source of chirality: D-Tartaric acid and asymmetric epoxidation
 Absolute configuration: 2S, 4S, 5R

5,6-Epoxy-2,4-dimethyl-N-methoxy-N-methylhexanamide



E.e. > 99% by precursor
 $[\alpha]_D^{15} -6.3 (c \ 0.16, \text{CHCl}_3)$
 Source of chirality: D-Tartaric acid and asymmetric epoxidation
 Absolute configuration: 2S, 4S, 5S

2,4-Dimethyl-5-hydroxy-N-methoxy-N-methylhexanamide




E.e. 92% based on the authentic compound

$[\alpha]_D^{22} -16.6$ (*c* 0.10, hexane)

Source of chirality: D-Tartaric acid and asymmetric epoxidation

Absolute configuration: 4*S*, 6*S*, 7*S*

7-Acetoxy-4,6-dimethyl-3-nonanone




E.e. = 100%

$[\alpha]_D^{20} = -56.1$ (*c*, 1.0 in MeOH)

3,5(*R*)-O-Benzylidene-D-glycero-D-gulo-heptono-1,4-lactone
 $C_{14}H_{16}O_7$

Source of chirality: D-glycero-D-gulo-heptono-1,4-lactone
as starting material




E.e. = 100%

$[\alpha]_D^{20} = -21.1$ (*c*, 1.1 in Me_2CO)

3,5(*R*):6,7(*R*)-Di-O-benzylidene-D-glycero-D-gulo-heptono-1,4-lactone
 $C_{21}H_{20}O_7$

Source of chirality: D-glycero-D-gulo-heptono-1,4-lactone
as starting material




E.e. = 100%

$[\alpha]_D^{20} = -90.6$ (*c*, 1.01 in MeCN)

5,7(*R*)-O-Benzylidene-D-glycero-D-gulo-heptono-1,4-lactone
 $C_{14}H_{16}O_7$

Source of chirality: D-glucose as starting material




E.e. = 100%

$[\alpha]_D^{20} = -64.7$ (*c*, 0.99 in MeCN)

5,7(R)-O-Benzylidene-D-glycero-D-ido-heptono-1,4-lactone
 $C_{14}H_{16}O_7$

Source of chirality: D-glucose as starting material




E.e. = 100%

$[\alpha]_D^{20} = -83.6$ (*c*, 1.04 in CHCl₃)

3,5(R)-O-Benzylidene-6,7-O-isopropylidene-2-O-trifluoromethanesulphonyl-D-glycero-D-gulo-heptono-1,4-lactone
 $C_{18}H_{19}F_3O_9S$

Source of chirality: D-glycero-D-gulo-heptono-1,4-lactone
as starting material




E.e. = 100%

$[\alpha]_D^{20} = -73.8$ (*c*, 0.52 in CHCl₃)

3,5(R)-O-Benzylidene-6,7-O-isopropylidene-D-glycero-D-ido-heptono-1,4-lactone
 $C_{17}H_{20}O_7$

Source of chirality: D-glycero-D-gulo-heptono-1,4-lactone
as starting material




E.e. = 100%

$[\alpha]_D^{20} = -67.1$ (*c*, 1.01 in MeCN)

3,5(R)-O-Benzylidene-D-glycero-D-ido-heptono-1,4-lactone
 $C_{14}H_{16}O_7$

Source of chirality: D-glycero-D-gulo-heptono-1,4-lactone
as starting material




E.e. = 100%

$[\alpha]_D^{20} = -100.3$ (*c*, 0.89 in CHCl₃)

5,7(R)-O-Benzylidene-2,3,6-O-triacetyl-D-glycero-D-gulo-heptono-1,4-lactone
C₂₀H₂₂O₁₀

Source of chirality: D-glucose as starting material




E.e. = 100%

$[\alpha]_D^{20} = -128.6$ (*c*, 1.02 in CHCl₃)

5,7(R)-O-Benzylidene-2,3,6-O-triacetyl-D-glycero-D-ido-heptono-1,4-lactone
C₂₀H₂₂O₁₀

Source of chirality: D-glucose as starting material




E.e. = 100%

$[\alpha]_D^{20} = -36.9$ (*c*, 0.99 in CHCl₃)

3,5(R)-O-Benzylidene-6,7-O-isopropylidene-D-glycero-D-gulo-heptono-1,4-lactone
C₁₇H₂₀O₇

Source of chirality: D-glycero-D-gulo-heptono-1,4-lactone
as starting material




E.e. = 100%

$[\alpha]_D^{20} = -19.2$ (*c*, 1.0 in CHCl₃)

3,5(R)-O-Benzylidene-6,7(S)-Di-O-benzylidene-D-glycero-D-gulo-heptono-1,4-lactone
C₂₁H₂₀O₇

Source of chirality: D-glycero-D-gulo-heptono-1,4-lactone
as starting material




E.e.= >99%

 $[\alpha]_D^{25} = -589.5$ (c = 1, CHCl₃)

Source of chirality: obtained from enantiopure R-(+)-1,1'-binaphthalene-2,2'-diol

C₂₀H₁₃O₃PS
 Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphhepin, 4-mercaptop, 4-sulfide



E.e.= > 99%

 $[\alpha]_D^{25} = -249.0$ (c = 1.1, CHCl₃)

Source of chirality: obtained from enantiopure R-(+)-1,1'-binaphthalene-2,2'-diol

Absolute configuration of C-2 uncertain

C₂₇H₂₁O₃PS

E.e.= > 99%

 $[\alpha]_D^{25} = +22.0$ (c = 0.8, CHCl₃)

Absolute configuration uncertain

C₇H₁₀S
Exo-2-Mercaptonorbornene



E.e.>99% [by HPLC (OptiPak TA)]


 $[\alpha]_D^{20} = -45.5$ (c 1.23, CHCl₃)

Source of chirality: Asymmetric methylation with MeLi

Absolute configuration: R

(assigned by correlation with R-alpha-phenethylamine)

N-(4-Methoxy-2-methylphenyl)-alpha-phenethylamine




E.e = 100 % [by GPC analysis of Mosher's derivatives of the corresponding amino ester and assuming that the reduction is non-racemizing]

Source of chirality : enzymic resolution

Absolute configuration : S

C₁₃H₁₅NO

2-amino-3-(2-naphthyl)propanol




E.e = 100 % [by GPC analysis of Mosher's derivatives of the corresponding amino ester and assuming that the reduction is non-racemizing]

Source of chirality : enzymic resolution

Absolute configuration : S

C₁₀H₁₅NO

2-amino-4-phenylbutanol




E.e = 100 % [by GPC analysis of Mosher's derivatives of the corresponding amino ester and assuming that the reduction is non-racemizing]

Source of chirality : enzymic resolution

Absolute configuration : S

C₁₀H₁₂F₃NO

2-amino-3-(4-trifluoromethylphenyl)propanol




D.e. >97% (by ¹H-NMR with 0.2 eq. Eu(fod)₃)
(S)-oct-1-yn-3-ol: $[\alpha]_D^{22} = -22,0$
(c=1.0, ether)

Source of chirality: (S)-phenylalanine


N-p-tosyl-(S)-phenylalanine (S)-oct-1-yn-3-yl ester

Th. Künstler, D. Schollmeyer, H. Singer*and M. Steigerwald



D.e. >97% (by $^1\text{H-NMR}$ with 0.2 eq. $\text{Eu}(\text{fod})_3$)
 (R)-1-phenylprop-2-yn-1-ol: $[\alpha]_D^{27} = -24.0$ ($c=2.1$, ethanol)
 Source of chirality: (S)-phenylalanine


N-p-tosyl-(S)-phenylalanine (R)-1-phenylprop-2-yn-1-yl ester

G. Bartoli, M. Bosco, C. Cimarelli, R. Dalpozzo, G. De Munno,
G. Palmieri

$\text{C}_{13}\text{H}_{14}\text{O}_2$
 2-benzoyl-5-Methyl-cyclopentanone


E.e. > 98%
 $[\alpha]_D^{20} = +14.9$ ($c = 1.9$, CHCl_3)

Source of chirality: (R)-(+)-1-phenylethylamine
 Absolute configuration 4S
 (assigned by chemical correlation)

G. Bartoli, M. Bosco, C. Cimarelli, R. Dalpozzo, G. De Munno,
G. Palmieri


$\text{C}_{18}\text{H}_{18}\text{O}_2$
 1,5-Diphenyl-4-methyl-pentan-1,3-dione

E.e. > 98 %
 $[\alpha]_D^{20} = +91.6$ ($c = 1.5$, CHCl_3); mp 77 °C
 Source of chirality: (R)-(+)-1-phenylethylamine
 Absolute configuration 4S
 (assigned by chemical correlation)

G. Bartoli, M. Bosco, C. Cimarelli, R. Dalpozzo, G. De Munno,
G. Palmieri

$\text{C}_{26}\text{H}_{27}\text{NO}$
 1,5-Diphenyl-3-(N-1'-phenylethyl)-amino-4-methyl-pent-2-en-1-one

E.e. > 98% (by nmr)
 $[\alpha]_D^{20} = -545.0$ ($c = 1.0$, CHCl_3)
 Source of chirality: (R)-(+)-1-phenylethylamine
 Absolute configuration 4S,1'R
 (assigned by X-Ray)




1-benzoyl-2-(N-1'-phenylethyl)-amino-3-methylcyclopentene

E.e. > 98% (by nmr)
 $[\alpha]_D^{20} = -459.4$ ($c = 1.1$, $CHCl_3$); mp 94-95 °C


Source of chirality: (R)-(+) -1-phenylethylamine

Absolute configuration 3S,1'R
 (assigned by X-Ray)




$C_{11}H_{12}OS$
2-p-Tolylsulfinyl-1,3-butadiene

E.e. = 100% (by chiral HPLC with chiral OB column)
 $[\alpha]_D^{20} = +174$ ($c = 2.0$, ethanol)
 Source of chirality : Synthesis by E_{2'} reaction of the corresponding sulfinylallylic bromide
 Absolute configuration : R




$C_{12}H_{14}OS$
3-Methyl-2-p-tolylsulfinyl-1,3-butadiene

E.e. = 100% (by chiral HPLC with chiral OB column)
 $[\alpha]_D^{20} = +252$ ($c = 0.75$, ethanol)
 Source of chirality : Synthesis by E_{2'} reaction of the corresponding sulfinylallylic bromide
 Absolute configuration : S




$C_{14}H_{18}OS$
3-Isopropyl-2-p-tolylsulfinyl-1,3-butadiene

E.e. = 100% (by chiral HPLC with chiral OB column)
 $[\alpha]_D^{20} = +234$ ($c = 2.0$, ethanol)
 Source of chirality : Synthesis by E_{2'} reaction of the corresponding sulfinylallylic bromide
 Absolute configuration : S




$C_{15}H_{18}OS$
1-(1-Cyclohexenyl)-1-p-tolylsulfinylethene

E.e. = 100% (by chiral HPLC with chiralcel OB column)
 $[\alpha]_D^{20} = +152$ ($c = 1.5$, ethanol)
 Source of chirality : Synthesis by E_2' reaction of the corresponding sulfinylallylic bromide
 Absolute configuration : S




$C_{13}H_{17}OSBr$
(E)-1-Bromo-4-methyl-2-p-tolylsulfinyl-2-pentene

E.e. $\geq 99\%$ (Inferred from e.e. of precursor)
 $[\alpha]_D^{25} = 79$ ($c = 1.50$, EtOH)
 Source of chirality : from (R)-(+)-p-tolylvinylsulfoxide (e.e. $\geq 99\%$)
 Absolute configuration : S




$C_{12}H_{15}OSBr$
1-Bromo-3-methyl-2-p-tolylsulfinyl-2-butene

E.e. $\geq 99\%$ (Inferred from e.e. of precursor)
 $[\alpha]_D^{25} = -142$ ($c = 1.00$, EtOH)
 Source of chirality : from (R)-(+)-p-tolylvinylsulfoxide (e.e. $\geq 99\%$)
 Absolute configuration : S




$C_{11}H_{13}OSBr$
(E)-1-Bromo-2-p-tolylsulfinyl-2-butene

E.e. $\geq 99\%$ (Inferred from e.e. of precursor)
 $[\alpha]_D^{25} = 67$ ($c = 1.25$, EtOH)
 Source of chirality : from (R)-(+)-p-tolylvinylsulfoxide (e.e. $\geq 99\%$)
 Absolute configuration : S



$C_{15}H_{19}OSBr$
2-Bromo-1-cyclohexylidene-1-p-tolylsulfinyl ethane

E.e. $\geq 99\%$ (Inferred from e.e. of precursor)
 $[\alpha]_D^{25} = -157$ ($c = 1.00$, EtOH)
 Source of chirality : from (R)-(+)-p-tolylvinyl-sulfoxide (e.e. $\geq 99\%$)
 Absolute configuration : S




$C_{16}H_{15}NO_3$

Absolute configuration: 1R, 2R, 3S, 4S, 5S, 6R

(assigned by comparison with the (+)-iodolactone)

$[\alpha]_D^{25}$ ($c=1.12 \times 10^{-2}$ g/mL, CHCl₃): - 70.0 \pm 0.5

Methyl (1R,2R,3S,4S,5S,6R)-2-exo-cyano-3-exo-phenyl-5,6-exo-epoxybicyclo[2.2.1]heptane-2-endo-carboxylate




$C_{16}H_{15}NO_3$

Absolute configuration: 1R, 2R, 3S, 4S, 5R, 6S

(assigned by comparison with the (+)-iodolactone)

$[\alpha]_D^{25}$ ($c=2.00 \times 10^{-2}$ g/mL, CHCl₃): - 8.5 \pm 0.5

Methyl (1R,2R,3S,4S,5R,6S)-2-exo-cyano-3-exo-phenyl-5,6-endo-epoxybicyclo[2.2.1]heptane-2-endo-carboxylate




$C_5H_{10}O_3$

Methyl 3-hydroxybutanoate

Absolute configuration : S

E.e. : 99% (GC, γ -cyclodextrin phase)

Source of chirality : enzymatic reduction



Absolute configuration :

S $C_7H_{14}O_3$


E.e.

>99% (GC, γ -cyclodextrin phase)

Ethyl 4-hydroxypentanoate

Source of chirality

enzymatic reduction



Absolute configuration :

S $C_8H_{16}O_3$


E.e.

>99% (GC, γ -cyclodextrin phase)

Ethyl 5-hydroxyhexanoate

Source of chirality

enzymatic reduction



Absolute configuration :

2R, 3S

D.e.

> 95% (GC, γ -cyclodextrin phase) $C_7H_{14}O_3$ [α]_D+7 (c = 1, CHCl₃)

Ethyl 2-methyl 3-hydroxybutanoate

Source of chirality

enzymatic reduction



Absolute configuration :

S $C_5H_{12}O_3$


E.e.

> 99% (GC, γ -cyclodextrin phase)

L-Lactaldehyde dimethyl acetal

Source of chirality


enzymatic reduction



Absolute configuration	:	R
E.e.	:	> 99% (GC, γ -cyclodextrin phase)
$[\alpha]_D$:	+31.8 (c = 0.5, CHCl ₃)
Ethyl 4-chloro 3-hydroxybutanoate	Source of chirality	: enzymatic reduction




Absolute configuration	:	S
E.e.	:	94% (GC, γ -cyclodextrin phase)
1-Phenylethanol	Source of chirality	: enzymatic reduction



S(-)styrene oxide

ee \rightarrow 50-80% [by nmr with Eu(hfc)₃]
 Source of chirality: Asymmetric epoxidation of styrene by chiral Ru(II) Schiff base complexes.
 Absolute configuration: S


 $C_{10}H_7F_3O$
1,1,1-Trifluoro-2-phenylbut-3-yne-2-ol

E.e. = >98% [by nmr of acetate with Eu(hfc)₃]
 $[\alpha]_D^{20} = -7.2$ (c 0.7, CH₂Cl₂)

Source of chirality: Lipase resolution.
 Absolute configuration (S)
 (follows from lipase resolution)

D. O'Hagan, N. A. Zaidi and R. B. Lamont

Tetrahedron: Asymmetry 1993, 4, 1703



E.e. = >98%


$[\alpha]_D^{20} = -12.1$ (c 1.9, CH₂Cl₂)

Source of chirality: Lipase resolution.
Absolute configuration (S)
(follows from lipase resolution)

C₁₇H₁₃F₃O
1,1,1-Trifluoro-2-benzyloxy-2-phenylbut-3-yne

D. O'Hagan, N. A. Zaidi and R. B. Lamont

Tetrahedron: Asymmetry 1993, 4, 1703



E.e. = >98%


$[\alpha]_D^{20} = +30.2$ (c 0.86, CH₂Cl₂)

Source of chirality: Lipase resolution.
Absolute configuration (R)
(follows from lipase resolution)

C₁₉H₁₅F₃O₃
Methyl 5,5,5-trifluoro-4-benzyloxy-4-phenylpent-2-yneate

D. O'Hagan, N. A. Zaidi and R. B. Lamont

Tetrahedron: Asymmetry 1993, 4, 1703



E.e. = >98%


$[\alpha]_D^{20} = -83.3$ (c 0.3, CH₂Cl₂)

Source of chirality: Lipase resolution.
Absolute configuration (R)
(follows from lipase resolution)

C₁₂H₁₃F₃O₃
Methyl 5,5,5-trifluoro-4-hydroxy-4-phenylpentanoate

D. O'Hagan, N. A. Zaidi and R. B. Lamont

Tetrahedron: Asymmetry 1993, 4, 1703



E.e. = >98%

$[\alpha]_D^{20} = -5.6$ (c 0.9, CH₂Cl₂)


Source of chirality: Lipase resolution.
Absolute configuration (R)
(follows from lipase resolution)

C₁₉H₁₉F₃O₃
Methyl 5,5,5-trifluoro-4-benzyloxy-4-phenylpentanoate

D. O'Hagan, N. A. Zaidi and R. B. Lamont

E.e. = >98%

$[\alpha]_D^{20} = -58.6$ (c0.6, CH₂Cl₂)



Source of chirality: Lipase resolution.
Absolute configuration (R)
(follows from lipase resolution)


C₁₁H₉F₃O₂

gamma-Phenyl-gamma-(trifluoromethyl)butyrolactone

D. O'Hagan, N. A. Zaidi and R. B. Lamont

E.e. = >98%

$[\alpha]_D^{20} = -63.2$ (c0.9, CH₂Cl₂)



Source of chirality: Lipase resolution.
Absolute configuration (S)
(follows from lipase resolution)


C₁₀H₉F₃O

1,1,1-Trifluoro-2-phenylbut-3-ene-2-ol

D. O'Hagan, N. A. Zaidi and R. B. Lamont

E.e. = >98%

$[\alpha]_D^{20} = -48.8$ (c1.6, CH₂Cl₂)



Source of chirality: Lipase resolution.
Absolute configuration (2R,3S)
(follows from lipase resolution)


C₁₀H₉F₃O₂

1,1,1-Trifluoro-2-phenyl-3,4-epoxybutane-2-ol

D. O'Hagan, N. A. Zaidi and R. B. Lamont

E.e. = >98%

$[\alpha]_D^{20} = -80$ (c0.44, CH₂Cl₂)



Source of chirality: Lipase resolution.
Absolute configuration (2R,3S)
(follows from lipase resolution)

C₁₁H₁₁F₃O₂

1,1,1-Trifluoro-2-methoxy-2-phenyl-3,4-epoxybutane